Actelion confirms $2.5B offer for ZS Pharma

Actelion is often thrown around as a possible buyout target--most recently, for deal-hungry Shire. But the Swiss biotech has its sights set on a pickup of its own. It's discussing a $2.5 billion buyout of ZS Pharma, it confirmed Thursday, sending shares of its target soaring. More from FierceBiotech